Since tretinoin is established as a differentiation therapy in acute leukemia [11], we sought to determine whether tretinoin treatment could induce the expression of GATA3 and FOXA1, which are key markers driving the luminal phenotype of bladder cancer [28,29]. The gene discussed is GATA3; the disease is urinary bladder carcinoma.